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ABSTRACT 
Background: Spinal cord pathology is an important substrate for long-term disability 
in multiple sclerosis (MS).  
 
Objective: To investigate longitudinal changes in spinal cord lesions and atrophy in 
patients with a non-spinal clinically isolated syndrome (CIS), and how they relate to 
the development of disability. 
 
Methods: 131 patients with a non-spinal CIS had brain and spinal cord imaging at 
the time of CIS and approximately 5 years later (median 5.2 years, range 3.0 – 7.9 
years). Brain MRI measures consisted of T2-hyperintense and T1-hypointense lesion 
loads plus brain atrophy. Spinal cord MRI measures consisted of lesion number and 
the upper cervical cord cross-sectional area (UCCA). Disability was measured using 
the Expanded Disability Status Scale (EDSS). Multiple linear regression was used to 
identify independent predictors of disability after 5 years. 
 
Results: During follow-up 93 (71%) patients  were diagnosed with MS. Baseline 
spinal cord lesion number, change in cord lesion number and change in UCCA were 
independently associated with EDSS (R2=0.53) at follow-up. Including brain T2 
lesion load and brain atrophy only modestly increased the predictive power of the 
model (R2=0.64).  
 
Conclusions: Asymptomatic spinal cord lesions and spinal cord atrophy contribute to 
the development of MS-related disability over the first 5 years after a non-spinal CIS. 
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INTRODUCTION 
Disability in people with multiple sclerosis (MS) is frequently referable to the spinal 
cord. Pathological studies  in MS show focal lesions involving grey and white matter, 
neuroaxonal loss and atrophy.1 Magnetic resonance imaging (MRI) often detects 
spinal cord abnormalities in established MS.1, 2 Focal T2-hyperintense lesions are 
seen in 75% or more of patients, most commonly in the cervical cord.2-4 Spinal cord 
atrophy can also be detected in vivo by measuring the upper cervical cord cross-
sectional area (UCCA)5 and has robust correlations with disability.3-13 
 
A clinically isolated syndrome (CIS) represents the first clinical manifestation of 
relapse-onset MS.14 Up to half of CIS patients have asymptomatic spinal cord 
lesions and these can be helpful in establishing a diagnosis of MS.15-17 Spinal cord 
lesions may also be of some prognostic value; in clinically isolated optic neuritis 
asymptomatic cord lesions are associated with an increased risk of disability after 5 
years.18 Spinal cord atrophy has been reported in CIS patients with T2-hyperintense 
brain lesions19, 20, a group known to be at high-risk for developing MS. Only one 
previous study has investigated spinal cord atrophy longitudinally in patients with CIS 
and no detectable change in UCCA was found over a follow-up period of one year.19 
This contrasts with findings in patients with established MS where progressive spinal 
cord atrophy is evident over follow-up periods of 12–36 months10-12 and may be 
associated with progression of disability.10, 12  
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We wanted to investigate longitudinal changes in spinal cord lesions and UCCA over 
the first 5 years after a CIS to elucidate whether spinal cord involvement is one of the 
mechanisms underlying disability in early relapse-onset MS.  
 
METHODS 
Patients 
Between 1995 and 2004 patients seen at Moorfields Eye Hospital and the National 
Hospital for Neurology and Neurosurgery with first demyelinating events were invited 
to take part in a prospective CIS cohort study. Patients aged 16-50 years with a 
typical CIS suggestive of MS and no previous neurological symptoms were included 
in the study. The patients were seen at baseline (within 12 weeks of CIS) and were 
followed up after approximately 5 years. Disability was measured using the 
Expanded Disability Status Scale (EDSS).21 All follow-up, EDSS assessments were 
done >4 weeks after a relapse or receiving corticosteroids. The currently used 
McDonald 2010 criteria17 were retrospectively applied to classify the diagnosis (i.e., 
MS or CIS) at follow up.  Patients who presented with a spinal cord CIS were 
excluded because we wanted to investigate the significance of clinically silent spinal 
cord MRI abnormalities at presentation. 
 
The study was approved by relevant institutional ethics committees. Informed 
consent was obtained at the time of study entry and at follow-up. 
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MRI acquisition 
MRI brain and spinal cord was done at baseline and follow-up on the same 1.5T 
Signa scanner (General Electric, Wisconsin, USA). There was a scanner upgrade 
during the study period that was considered in statistical analyses (see below). 
 
The acquisition protocol has been described in detail elsewhere.18, 19 MRI of the 
brain included 46 x 3mm contiguous axial proton density (PD)/T2-weighted images 
obtained using a dual-echo fast spin sequence (TR 3200ms, TE 15 / 90ms, matrix 
256x256, FOV 24cm) and post-contrast T1-weighted fast spin echo axial images (TR 
600ms, TE 14ms, matrix 256x256, FOV 24cm). MRI of the spinal cord comprised 
9x3mm contiguous sagittal PD/T2-weighted images (TR 2500ms, TE 56/92ms) of 
the whole cord and a volume acquired inversion prepared fast spoiled gradient echo 
(FSPGR) scan of the cervical cord (TR 15.6ms, TE 4.2ms, matrix 256x256, FOV 
25cm) with 60×1mm sagittal slices. 
 
Image analysis 
Lesion measures 
The number of T2-hyperintense brain and spinal cord lesions plus T1-hypointense 
brain lesions was recorded at baseline and follow-up. The lesions were identified by 
a single experienced neuroradiologist, who was blinded the patient’s clinical status. 
T2-hyperintense and T1-hypointense brain lesions were outlined using a semi-
automated edge finding tool (JIM6, Xinapse systems, Aldwincle, UK). T2 lesion 
volume (T2LV) and T1 lesion volume (T1LV) was calculated by multiplying lesion 
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area by slice thickness. The change in T2LV, T1LV and spinal cord lesion number 
between baseline and follow-up was calculated (Figure 1). 
 
Brain atrophy 
Normalised brain volume (NBV) at baseline was calculated using SIENAX and the 
percentage brain volume change (PBVC) between baseline and follow-up using 
SIENA from T1-weighted fast spin echo scans after filling T1-hypointense lesions.22, 
23 SIENAX and SIENA analyses were done using FMRIB Software Library (FSL) 
version 5.0.2. 
 
Spinal cord atrophy 
UCCA was measured from FSPGR scans of the cervical cord at baseline and follow-
up. In line with previously described studies, sagittally-acquired images were 
reformatted in the axial plane to obtain five contiguous 3mm slices at the level of the 
C2/C3 disc5 and an active surface model was used to measure the mean UCCA 
over the five slices6, 24, 25 All UCCA measurements were done by a single observer. 
Change in UCCA between baseline and follow-up was recorded (Figure 1). 
 
Statistical analysis 
Patients were grouped based on clinical status at follow-up as CIS, MS with EDSS 
<3 and MS with EDSS ≥3. Univariable comparisons of MRI measures between 
binary groups (disabled or not, MS or CIS) were examined using the Wilcoxon rank 
7 
 
sum test for lesion and brain atrophy measures, due to their skewed distribution. 
Linear regression was used for comparisons of UCCA, with age and sex as 
covariates.   
 
Multiple linear regression models were used to identify independent MRI predictors 
of EDSS at follow-up and the change in EDSS between baseline and follow-up. 
Firstly, separate models were constructed for brain and spinal cord MRI measures in 
order to compare the proportion of variance explained using the R-square (R2) 
statistic and to restrict the number of covariates. Only variables with p<0.08 were 
retained in models. Potential confounding by age and sex was examined by entering 
these into the final models; non-linear effects of continuous MRI predictors and their 
changes were examined by fitting quadratic terms, and of count predictors by 
entering these in categorical form. Secondly, the predictor variables from the 
separate brain and spinal cord models were combined, and manual backwards 
stepwise elimination used to find the best combined model. Omitted MRI variables 
were then entered singly and retained if p<0.08. Disease duration (i.e. time from CIS 
onset to follow-up) was included as a covariate in all models. The potential effect of a 
scanner upgrade during the follow-up period was assessed by adjusting for those 
subjects whose baseline and follow-up straddled the upgrade.  
 
Linear regression allows convenient and valid identification of independent predictors 
of EDSS and assessment of the proportion of variance explained. Two possible 
disadvantages are: (1) potential violation of the regression residual assumptions; it is 
important to note that the required assumption is not the normal distribution of 
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EDSS, but of the residuals after regression; however, even though there was no 
evidence of residual non-normality or heteroscedasticity, inference from final models 
was confirmed using a non-parametric bias-corrected and accelerated bootstrap26 
with 1000 replicates; (2) although regression p-values, confidence intervals and R2 
are valid after the residual checks above, the regression coefficients for EDSS must 
be interpreted with caution and used comparatively rather than absolutely, since the 
EDSS scale is non-linear. 
 
Statistical analysis used Stata 13.1 (Stata Corporation, Texas, USA).  Significance is 
reported at the level of p<0.05. 
 
 
RESULTS 
131 non-spinal CIS patients (mean age 32.6 years, 83 [63%] female) were seen at 
baseline (mean 47 days after CIS, range 6–88 days) and for follow-up after a mean 
of 5.3 years (median 5.2 years, interquartile range 1.6 years, range 3.0–7.9 years). 
78 (60%) patients were seen for follow-up within 5±1 year of CIS. The cohort 
included 114 (87%) patients with optic neuritis, 16 (12%) patients with a 
brainstem/cerebellar syndrome and 1 (1%) patient with a hemispheric syndrome. 
 
During follow-up 93 (71%) patients were diagnosed with MS using the McDonald 
2010 criteria. 15 (16%) patients had an EDSS score of ≥3  at follow-up (median 
EDSS 3.5, range 3–6.5), and were classified as disabled. Four of these patients had 
developed secondary progressive MS. 78 (84%) MS patients had not developed 
significant disability (median EDSS 1, range 0–2.5). Disability was similar at follow-
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up in patients with optic neuritis and other CIS presentations (median EDSS 1 in 
both groups). During follow-up 23 (18%) patients started disease-modifying 
treatment (DMT, either beta interferon or glatiramer acetate). Only one CIS patient 
was treated before a second clinical attack. The proportion of males was higher 
among patients who remained CIS (53% vs 37%) which is in keeping with female 
sex being a risk factor for conversion to MS in patients with CIS.  
 
Characteristics of the CIS cohort grouped by clinical status at follow-up are shown in 
Table 1. 
 
Brain MRI abnormalities 
Brain MRI findings at baseline and at follow-up are shown in Table 1. MS patients 
classified as disabled at follow-up (EDSS ≥3) had a greater T2LV at baseline (means 
5.12 vs 1.72ml, p<0.001) and follow-up (18.20 vs 4.89ml, p<0.001) compared with 
the MS patients without significant disability. The findings were similar for brain T1LV 
at baseline (0.65 vs 0.21ml, p=0.009) and at follow-up (5.06 vs 0.64ml, p=0.031). 
The annualised PBVC showed significantly more atrophy in the patients with MS 
compared with those who remained CIS (-0.40 vs -0.26%, p=0.009), and in the MS 
patients who were disabled at follow-up compared with those without disability (-0.67 
vs -0.35%, p=0.047). 
 
 
Spinal cord MRI abnormalities 
Spinal cord MRI measures at baseline and follow-up are shown in Table 1. 
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Spinal cord lesions 
There was no difference in the number of spinal cord lesions at baseline in patients 
with optic neuritis and a non-optic neuritis CIS. None of the patients who remained 
CIS had spinal cord lesions either at baseline or follow-up. Among patients who were 
diagnosed with MS, the number of spinal cord lesions at baseline (median [range] 2 
[0 – 7] vs 0 [0 – 5], p=0.001) and at follow-up (median [range] 5 [1 – 14] vs 1 [0 – 9], 
p<0.001) was higher in patients with disability compared with those without 
significant disability.  
 
Spinal cord atrophy 
The mean UCCA at baseline and follow-up grouped by clinical status at follow-up is 
shown in Figure 2.  
 
There was no difference in the mean UCCA at baseline in patients with optic neuritis 
and a non-optic neuritis CIS. After adjusting for age and sex there was no significant 
difference in the UCCA at baseline in patients who developed MS compared with 
those who remained CIS, (unadjusted means 74.66 vs 78.25mm2, adjusted 
difference in means -2.21, p=0.11), or in MS patients with and without disability at 
follow-up (unadjusted means 76.65 vs 74.27mm2, adjusted difference 2.22, p=0.27). 
The mean annualised change in UCCA showed significantly more atrophy  in 
patients with MS compared with those who remained CIS (unadjusted means -0.42 
vs -0.09mm2/year, adjusted difference -0.37, p<0.001), and in MS patients with 
disability compared with those without significant disability (unadjusted means -0.91 
vs -0.32 mm2/year, adjusted difference -0.59, p<0.001).  
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Independent associations between MRI measures and disability 
Multivariable regression models were constructed that included brain MRI measures 
only, spinal cord MRI measures only and the combination of both (Tables 2 and 3) in 
order to determine independent associations between MRI measures and disability. 
Age, sex and scanner upgrade all had a negligible effect on regression coefficients 
and were not retained in the models. Change in T2LV showed evidence of a non-
linear association with EDSS, and the squared term was therefore retained in 
models. 
 
Multivariable linear regression: EDSS at follow-up 
In the brain MRI model the change in T2LV, squared change in T2LV and PBVC 
were independently associated with EDSS (R2=0.39). The small negative coefficient 
for squared change in T2LV suggests a levelling off, as volume increases of the 
association between T2LV growth and higher EDSS. In the spinal cord model 
baseline cord lesion number, change in cord lesion number and change in UCCA 
were independently associated with EDSS (R2=0.53).  
 
When the brain and spinal cord MRI measures were combined all the measures from 
the separate models above remained significant, and baseline UCCA became 
borderline significant.  Combining brain and spinal cord MRI measures only modestly 
increased the predictive power of the model (adjusted R2=0.61) compared to spinal 
cord measures alone (adjusted R2=0.51). Bootstrapping confirmed the regression 
results, except for baseline UCCA in the combined model which became borderline 
significant (Table 2). Excluding patients with a non-optic neuritis presentation (n=17) 
made no material difference to any of the models. 
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Spinal cord lesion number was the only baseline MRI measure associated with 
disability at follow-up. Univariably, baseline spinal cord lesion number explained a 
significant proportion of the variability in EDSS at follow-up (adjusted R2=0.24).  
 
Because of differences in the length of follow-up from presentation with CIS (range 
3.0 – 7.9) we adjusted for disease duration (i.e., from onset of CIS to last follow up) 
in all models reported. Omission of disease duration from the models did not 
materially affect the results. We did not adjust for DMT use in the models. Patients 
who started DMT had greater disability at follow-up (mean EDSS 2.28 vs 1.21, 
p<0.001), likely reflecting reverse causality with more severely affected patients 
receiving treatment. This is consistent with the greater change in T2LV (p<0.001), 
PBVC (p=0.003), cord lesion number (p<0.001), and UCCA (p=0.034) in patients 
who received DMT. Since these differences also likely reflect reverse causality, 
adjustment for DMT is not appropriate27 being plausibly in the causal pathway 
between the MRI measures and EDSS, with a DMT covariate tending to “steal” the 
effect of MRI variables. Nevertheless when DMT was entered into the model it was 
no longer associated with EDSS (p=0.174) and all of the MRI variables remained 
significant, except baseline UCCA. 
 
Multivariable linear regression: Change in EDSS baseline to follow-up 
We repeated analyses using change in EDSS from baseline to follow-up as the 
dependent variable (Table 3), largely confirming findings above. In the brain only 
model change in T2LV and the squared change in T2LV were associated with the 
change EDSS (adjusted R2=0.26) while in the spinal cord only model baseline spinal 
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cord lesion number, change in spinal cord lesion number and with borderline 
significance the change in UCCA were associated with the change in EDSS 
(adjusted R2=0.32). In the combined model all of the MRI measures remained 
significant except the change in UCCA, and PBVC became borderline significant 
(confirmed with bootstrapping). The adjusted R2 for the combined model for change 
in EDSS was 0.37. 
 
DISCUSSION 
In this prospectively recruited CIS cohort followed longitudinally from disease onset, 
spinal cord MRI abnormalities explained more of the variability in disability after 
approximately 5 years than brain MRI measures. These findings suggest that spinal 
cord abnormalities, detected using MRI, may be important in the evolution of 
disability in the early years following a non-spinal CIS. 
 
Previous studies in patients with established MS have generally found a poor 
correlation between spinal cord lesion load and disability.2-4 Many studies have been 
cross-sectional in nature and included MS patients with different disease durations 
and clinical courses, whereas our cohort was followed longitudinally from disease 
onset. We have previously reported in a subgroup of these patients with optic 
neuritis that asymptomatic spinal cord lesions at the time of CIS are associated with 
disability after 5 years.18 In this study we confirm the importance of cord lesions at 
baseline in a larger cohort and also found that change in cord lesion load was 
independently associated with disability.  
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Because of their location in or close to pathways involved in locomotor and sphincter 
function, spinal cord lesions may cause physical dysfunction more often than brain 
lesions (although the latter may also do so when they are in clinically eloquent 
locations, e.g. the brainstem). New  spinal cord lesions seen on MRI are more likely 
to be symptomatic than new brain lesions28 and cord relapses are more likely to 
leave residual neurological impairment.29 The spinal cord lesions seen at baseline in 
our study were clinically silent. How they contribute to future disability is uncertain, 
although one potential explanation is that axonal loss in focal lesions reduces the 
functional reserve to prevent permanent deficits when new pathological changes 
develop in the future. Whether the importance of focal spinal cord lesion 
accumulation lessens over time, particularly after the onset of secondary 
progression, is uncertain. Previous studies in patients with progressive MS have 
found no relationship between cord lesions and disability.3, 4 However, a recent study 
at 3T that quantified cervical cord lesion load on axial images with high in-plane 
resolution found cord lesion load was independently associated with disability in 
relapsing and progressive forms of MS, and a higher lesion load was seen in 
patients with progressive MS.30  
 
In addition to focal lesions, we found that the change in UCCA was independently 
associated with disability at follow-up. Spinal cord atrophy in MS reflects 
neuroaxonal loss from the effects of axonal transection and Wallerian degeneration 
(arising from focal lesions) but also diffuse changes in the normal appearing grey 
and white matter.1 Spinal cord atrophy, as measured by the UCCA, has been  
correlated with disability in established MS.3-9, 13 Spinal cord atrophy begins early in 
the course of MS with evidence of spinal cord atrophy in CIS patients with MRI brain 
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abnormalities19, 20 (a group at high-risk for MS), compared with healthy controls. 
Smaller baseline UCCA in this study was associated with EDSS at follow-up, 
although with borderline significance. 
 
Few studies have evaluated longitudinal changes in spinal cord atrophy in patients 
with CIS. In a pilot study from this cohort no change in UCCA was seen over a 
follow-up period of one year.19 In a small study of patients with early relapsing-
remitting MS (disease duration <3 years), the rate of spinal cord atrophy was 
significantly greater than in healthy controls.11 However, there was no correlation 
between cord atrophy and change in disability over 3 years. This contrasts with our 
own findings that significantly greater spinal cord atrophy occurred in MS patients 
and that the change in UCCA was associated with EDSS at follow-up. Our positive 
findings might be explained by the longer duration of follow-up, larger sample size or 
the use of a more robust method for detecting spinal cord atrophy.5, 25  
 
Spinal cord imaging is technically challenging and adds additional time to the brain 
MRI.31 In clinical practice spinal cord MRI is not always used in the diagnosis and 
monitoring of patients with MS. Recent European and North American guidelines 
recommend that spinal cord imaging be considered in CIS patients presenting with a 
spinal cord syndrome and in those patients where brain imaging is not diagnostic of 
MS.32, 33 Whether routine spinal cord imaging should be done in patients with a non-
spinal CIS is controversial.34 Our findings suggest that spinal cord imaging may not 
only be helpful diagnostically16, but may also provide significant prognostic 
information. Spinal cord atrophy is currently not able to be monitored in the clinical 
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setting, although fully automated methods for measuring the UCCA are in 
development and appear to have a good correlation with semi-automated 
measures.35  
 
Some limitations should be noted. Firstly, only a minority of patients developed 
significant disability over the 5 year follow-up period. Whether early spinal cord MRI 
abnormalities retain their prognostic significance in the longer term is uncertain. 
Future work in this and other CIS cohorts should address how early changes brain 
and spinal cord MRI measures relate to the development of long-term disability. 
Secondly, the study did not include a matched healthy control group for comparison. 
However, in a previously reported study, the annualised decrease in UCCA was 
significantly greater in early relapsing-remitting MS patients than in healthy controls, 
and in that study no significant change in UCCA was observed in the healthy control 
group over a follow-up period of up to 3 years.11 Thirdly, patients with optic neuritis 
are over-represented in this cohort with only a relatively small number of patients 
with other non-spinal CIS types. In some studies optic neuritis appears to be 
associated with a better prognosis than other CIS types.36 However, almost 80% of 
the cohort had an abnormal baseline MRI scan indicating a group at high-risk for the 
development of MS. Fourth, we didn’t consider the location of brain and spinal cord 
lesions. Infratentorial lesions in patients with CIS have been associated with an 
increased risk of future disability in previous studies that have not included spinal 
cord imaging.37 Also, the level of spinal cord lesions (e.g. cervical, thoracic or 
lumbar) may influence clinical symptoms and disability and this was not recorded in 
this study. Fifth, although much of the disability observed over the follow-up period is 
likely to be related to the effects of relapses, information on the number of relapses 
17 
 
during the follow-up period was not available to include as a covariate in statistical 
models. Finally, we measured disability using the EDSS score, a scale that is 
weighted towards locomotor and ambulatory dysfunction and therefore potentially 
more sensitive to spinal cord dysfunction, and less sensitive to other aspects of MS-
related disability. The EDSS is, nevertheless, still the most widely used and accepted 
scale for monitoring the evolution of MS in clinical trials and natural history studies.  
 
In conclusion, we found that spinal cord MRI measures were more strongly 
associated with physical disability than brain MRI measures in the first 5 years after 
a non-spinal CIS. These findings suggest that spinal cord lesions and atrophy may 
be important in the evolution of disability in early relapse-onset MS. 
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Table 1. Baseline demographic characteristics and MRI findings at baseline and 
follow grouped by clinical status after 5 years. 
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CIS at 5 years 
(n=38) 
MS after 5 years  
 
p† 
All patients 
(n=131) 
EDSS < 3 
(n=78) 
EDSS ≥ 3 
(n=15) 
Demographic and clinical characteristics   
   Age, years 32.6 (7.5) 32.5 (6.9) 32.8 (7.9) 31.5 (7.4) 0.597 
   Female, n (%) 83 (63) 18 (47) 55 (71) 10 (67) 0.766 
   Optic neuritis, n (%)  114 (87) 34 (89) 69 (88) 11 (73) 0.122 
   Baseline EDSS, median 
(IQR) 
1 (1) 1 (1)   1 (1) 1 (1.75) 0.069 
Baseline MRI measures        
   Brain T2LV, ml  1.63 (3.0) 0.06 (0.1) 1.72 (2.9) 5.12 (4.1) <0.001 
   Brain T1LV, ml  0.20 (0.6) 0 (0) 0.21 (0.6) 0.65 (1.1) 0.009 
   NBV, cm3 1576 (72) 1580 (66) 1582 (68) 1549 (82) 0.210 
   SC lesion number, n  0.54 (1.2) 0 (0) 0.50 (0.9) 2.07 (1.9)  <0.001 
   UCCA, mm2  75.70 (7.8) 78.25 (7.2) 74.27 (7.7) 76.65 (7.8) 0.270 
Annualised change in MRI measures   
    Δ Brain T2LV, ml 0.56 (1.3) 0 (0) 0.51 (0.8) 2.28 (2.8) <0.001 
    Δ Brain T1LV, ml 0.12 (0.5) 0 (0) 0.07 (0.1) 0.67 (1.4) 0.031 
    PBVC, % -0.37 (0.3) -0.26 (0.2) -0.35 (0.3) -0.67 (0.5) 0.047 
    Δ  SC lesion number, n 0 (0.3) 0 (0) 0 (0.4) 0.83 (1.1) <0.001 
    Δ UCCA, mm2 -0.32 (0.5) -0.09 (0.3) -0.32 (0.4) -0.91 (0.8) <0.001 
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All data presented as mean (SD) unless otherwise stated. 
Abbreviations: Δ = change; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; NBV = normalised brain 
volume; PBVC = percentage brain volume change; SC = spinal cord; T2LV = T2 lesion volume; T1LV = T1 lesion volume; UCCA = 
upper cervical cord cross-sectional area.  
† p values for comparisons between MS patients with EDSS <3 and ≥3 at follow-up. 
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Table 2. Multiple linear regression models investigating independent associations of MRI measures with EDSS after 5 years in 
patients with a non-spinal CIS  
 
Disease duration was included as a covariate in all models. 
Abbreviations: CI = confidence interval; NBV = normalised brain volume; PBVC = percentage brain volume change; SC = spinal 
cord; T2LV = T2 lesion volume; UCCA = upper cervical cord cross-sectional area. 
*Bootstrap confidence interval and p-value. 
MRI measure          Coefficient 95% CI p R2 (Adjusted R2) 
Brain MRI measures    0.39 (0.37) 
     Change in T2LV 0.19 0.12 , 0.26 <0.001  
     Squared Change in T2LV -0.0032 -0.0047 ,  -0.0017 <0.001  
     PBVC -0.14 -0.25, -0.02 0.020  
Spinal cord MRI measures    0.53 (0.51) 
     Baseline SC lesion number 0.40 0.26 , 0.54 <0.001  
     Change in SC lesion number 0.19 0.11 , 0.28 <0.001  
     Change in UCCA -0.15 -0.21 , -0.09 <0.001  
Brain and spinal cord MRI measures combined    0.64 (0.61) 
     Change in T2LV 0.10 0.04 , 0.16 0.002  
     Squared Change in T2LV -0.0017 -0.0029, -0.00039 0.011  
     PBVC -0.11 -0.21 , -0.02 0.018  
     Baseline SC lesion number 0.37 0.24 , 0.50 <0.001  
     Change in SC lesion number 0.12 0.04 , 0.21 0.004  
     Baseline UCCA -0.01 -0.033 , 0.0040 
(-0.028, 0.00036*) 
0.122 
(0.053*) 
 
     Change in UCCA -0.11 -0.18  -0.05 <0.001  
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Table 3. Multiple linear regression models investigating independent associations of MRI measures with change in EDSS from 
baseline to follow-up in patients with a non-spinal CIS  
 
Disease duration was included as a covariate in all models. 
Abbreviations: CI = confidence interval; NBV = normalised brain volume; PBVC = percentage brain volume change; SC = spinal 
cord; T2LV = T2 lesion volume; UCCA = upper cervical cord cross-sectional area. 
*Bootstrap confidence interval and p-value. 
MRI measure          Coefficient 95% CI p R2 (Adjusted R2) 
Brain MRI measures    0.29 (0.26) 
     Change in T2LV 0.23 0.14, 0.32 <0.001  
     Squared Change in T2LV -0.003 -0.006, -0.002 0.037  
Spinal cord MRI measures    0.34 (0.32) 
     Baseline SC lesion number 0.30 0.15 , 0.53 <0.001  
     Change in SC lesion number 0.24 0.12 , 0.34 0.002  
     Change in UCCA -0.08 -0.16, 0.005 
(-0.19 , -0.0004*) 
0.066 
(0.055*) 
 
Brain and spinal cord MRI measures combined    0.42 (0.37) 
     Change in T2LV 0.15 0.06 , 0.24 0.002  
     Squared Change in T2LV -0.002 -0.004, -0.0007 0.007  
     PBVC -0.12 -0.26 , 0.01 
(-0.33, -0.005*) 
0.070 
(0.045*) 
 
     Baseline SC lesion number 0.26 0.07 , 0.45 0.007  
     Change in SC lesion number 0.15 0.03 , 0.27 0.016  
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Figure 1. T2-weighted sagittal images of the whole spine (A) and reformatted axial 
images from volumetric T1-weighted scans of the cervical spinal cord at the level of 
C2 /C3 (B), obtained at baseline (left) and follow-up (right).  Figure 1A shows three 
spinal cord lesions at baseline and five lesions at follow-up (arrows). Figure 1B 
24 
 
shows the upper cervical cord cross-sectional area (outlined in red). The mean 
UCCA was 72.08 mm2 at baseline and 61.28 mm2 after 5 years.
25 
 
 
 
 
Figure 2. Change in upper cervical cord area from baseline to 5 years grouped by disability status at follow-up. 
26 
 
References 
1. Kearney H, Miller DH and Ciccarelli O. Spinal cord MRI in multiple sclerosis-
diagnostic, prognostic and clinical value. Nat Rev Neurol. 2015; 11: 327-38. 
 
2. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array 
coils and fast spin echo. II. Findings in multiple sclerosis. Neurology. 1993; 43: 2632-
7. 
 
3. Lukas C, Sombekke MH, Bellenberg B, et al. Relevance of spinal cord 
abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large 
cohort of patients. Radiology. 2013; 269: 542-52. 
 
4. Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord 
abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical 
subtypes and symptoms. Brain. 1998; 121: 687-97. 
 
5. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in 
multiple sclerosis. A new reproducible and sensitive MRI method with potential to 
monitor disease progression. Brain. 1996; 119: 701-8. 
 
6. Rocca MA, Horsfield MA, Sala S, et al. A multicenter assessment of cervical 
cord atrophy among MS clinical phenotypes. Neurology. 2011; 76: 2096-102. 
 
7. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability 
in MS: a longitudinal study. Neurology. 1998; 51: 234-8. 
 
8. Furby J, Hayton T, Anderson V, et al. Magnetic resonance imaging measures 
of brain and spinal cord atrophy correlate with clinical impairment in secondary 
progressive multiple sclerosis. Mult Scler. 2008; 14: 1068-75. 
 
9. Bonati U, Fisniku LK, Altmann DR, et al. Cervical cord and brain grey matter 
atrophy independently associate with long-term MS disability. J Neurol Neurosurg 
Psychiatry. 2011; 82: 471-2. 
 
10. Lukas C, Knol DL, Sombekke MH, et al. Cervical spinal cord volume loss is 
related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg 
Psychiatry. 2015; 86: 410-8. 
 
11. Rashid W, Davies GR, Chard DT, et al. Increasing cord atrophy in early 
relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry. 
2006; 77: 51-5. 
 
12. Lin X, Tench CR, Turner B, Blumhardt LD and Constantinescu CS. Spinal 
cord atrophy and disability in multiple sclerosis over four years: application of a 
reproducible automated technique in monitoring disease progression in a cohort of 
the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry. 2003; 
74: 1090-4. 
 
27 
 
13. Kearney H, Rocca MA, Valsasina P, et al. Magnetic resonance imaging 
correlates of physical disability in relapse onset multiple sclerosis of long disease 
duration. Mult Scler. 2014; 20: 72-80. 
 
14. Brownlee WJ and Miller DH. Clinically isolated syndromes and the 
relationship to multiple sclerosis. J Clin NeuroscI 2014; 21: 2065-71. 
 
15. O'Riordan JI, Losseff NA, Phatouros C, et al. Asymptomatic spinal cord 
lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes 
suggestive of demyelination. J Neurol Neurosurg Psychiatry. 1998; 64: 353-7. 
 
16. Sombekke MH, Wattjes MP, Balk LJ, et al. Spinal cord lesions in patients with 
clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology. 
2013; 80: 69-75. 
 
17. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple 
sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011; 69: 292-302. 
 
18. Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: The 
risk for disability. Neurology. 2009; 72: 542-50. 
 
19. Brex PA, Leary SM, O'Riordan JI, et al. Measurement of spinal cord area in 
clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg 
Psychiatry. 2001; 70: 544-7. 
 
20. Biberacher V, Boucard CC, Schmidt P, et al. Atrophy and structural variability 
of the upper cervical cord in early multiple sclerosis. Mult Scler. 2015; 21: 875-84. 
 
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded 
disability status scale (EDSS). Neurology. 1983; 33: 1444. 
 
22. Prados F, Cardoso MJ, MacManus D, Wheeler-Kingshott CA and Ourselin S. 
A modality-agnostic patch-based technique for lesion filling in multiple sclerosis. Med 
Image Comput Comput Assist Interv. 2014; 17: 781-8. 
 
23. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated 
longitudinal and cross-sectional brain change analysis. NeuroImage. 2002; 17: 479-
89. 
 
24. Horsfield MA, Sala S, Neema M, et al. Rapid semi-automatic segmentation of 
the spinal cord from magnetic resonance images: application in multiple sclerosis. 
NeuroImage. 2010; 50: 446-55. 
 
25. Kearney H, Yiannakas MC, Abdel-Aziz K, et al. Improved MRI quantification 
of spinal cord atrophy in multiple sclerosis. J Magn Reson Imaging. 2014; 39: 617-
23. 
 
26. Carpenter J and Bithell J. Bootstrap confidence intervals: when, which, what? 
A practical guide for medical statisticians. Stat Med. 2000; 19: 1141-64. 
 
28 
 
27. Weinberg CR. Toward a Clearer Definition of Confounding. Am J Epidemiol. 
1993; 137: 1-8. 
 
28. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the 
brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology. 1996; 
46: 373-8. 
 
29. Leone M, Bonissoni S, Collimedaglia L, et al. Factors predicting incomplete 
recovery from relapses in multiple sclerosis: a prospective study. Mult Scler. 2008; 
14: 485-93. 
 
30. Kearney H, Altmann DR, Samson RS, et al. Cervical cord lesion load is 
associated with disability independently from atrophy in MS. Neurology. 2015; 84: 
367-73. 
 
31. Wheeler-Kingshott CA, Stroman PW, Schwab JM, et al. The current state-of-
the-art of spinal cord imaging: applications. NeuroImage. 2014; 84: 1082-93. 
32. Rovira A, Wattjes MP, Tintore M, et al. Evidence-based guidelines: MAGNIMS 
consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation 
in the diagnostic process. Nat Rev Neurol. 2015; 11: 471-82. 
 
33. Traboulsee A, Simon JH, Stone L, et al. Revised Recommendations of the 
Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical 
Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J 
Neuroradiol. 2015. 
 
34. Hutchinson M. Spinal cord MRI should always be performed in clinically 
isolated syndrome patients: Commentary. Mult Scler. 2014; 20: 1690-1. 
 
35. Yiannakas MC, Mustafa AM, De Leener B, et al. Fully automated 
segmentation of the cervical cord from T1-Weighted MRI using PropSeg: Application 
to multiple sclerosis. NeuroImage Clin 2015; 10:71-7 
36. Tintore M, Rovira A, Rio J, et al. Is optic neuritis more benign than other first 
attacks in multiple sclerosis? Ann Neurol. 2005; 57: 210-5. 
37. Tintore M, Rovira A, Arrambide G, et al. Brainstem lesions in clinically isolated 
syndromes. Neurology. 2010; 75: 1933-8.  
